These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 26065480)

  • 1. Adoptive therapy for EBV-induced cancers: driving success with post-transplant lymphoproliferative disorder to other EBV-derived tumors.
    Smith C; Khanna R
    Immunotherapy; 2015; 7(5):563-72. PubMed ID: 26065480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
    Davis JE; Moss DJ
    Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive T-Cell Immunotherapy.
    Gottschalk S; Rooney CM
    Curr Top Microbiol Immunol; 2015; 391():427-54. PubMed ID: 26428384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy.
    Sherritt MA; Bharadwaj M; Burrows JM; Morrison LE; Elliott SL; Davis JE; Kear LM; Slaughter RE; Bell SC; Galbraith AJ; Khanna R; Moss DJ
    Transplantation; 2003 May; 75(9):1556-60. PubMed ID: 12792514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for Epstein-Barr virus-associated tumors.
    Comito MA; Sun Q; Lucas KG
    Leuk Lymphoma; 2004 Oct; 45(10):1981-7. PubMed ID: 15370241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
    Burns DM; Crawford DH
    Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive cell therapy against EBV-related malignancies: a survey of clinical results.
    Merlo A; Turrini R; Dolcetti R; Zanovello P; Amadori A; Rosato A
    Expert Opin Biol Ther; 2008 Sep; 8(9):1265-94. PubMed ID: 18694349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments.
    Neparidze N; Lacy J
    Clin Adv Hematol Oncol; 2014 Jun; 12(6):358-71. PubMed ID: 25003566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
    Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
    J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts.
    O'Reilly RJ; Small TN; Papadopoulos E; Lucas K; Lacerda J; Koulova L
    Immunol Rev; 1997 Jun; 157():195-216. PubMed ID: 9255631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory T cells and EBV associated malignancies.
    Li J; Qian CN; Zeng YX
    Int Immunopharmacol; 2009 May; 9(5):590-2. PubMed ID: 19539572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adoptive immune therapy using EBV-specific CTL].
    Kuzushima K; Morishima T
    Nihon Rinsho; 1997 Feb; 55(2):473-8. PubMed ID: 9046843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient.
    Aris RM; Maia DM; Neuringer IP; Gott K; Kiley S; Gertis K; Handy J
    Am J Respir Crit Care Med; 1996 Dec; 154(6 Pt 1):1712-7. PubMed ID: 8970360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.
    Subklewe M; Sebelin K; Block A; Meier A; Roukens A; Paludan C; Fonteneau JF; Steinman RM; Münz C
    Hum Immunol; 2005 Sep; 66(9):938-49. PubMed ID: 16360833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection.
    Mautner J; Bornkamm GW
    Eur J Cell Biol; 2012 Jan; 91(1):31-5. PubMed ID: 21458882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive cellular immunotherapy for EBV lymphoproliferative disease.
    Heslop HE; Rooney CM
    Immunol Rev; 1997 Jun; 157():217-22. PubMed ID: 9255632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target.
    Tse E; Kwong YL
    Exp Mol Med; 2015 Jan; 47(1):e136. PubMed ID: 25613733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of cytotoxic T lymphocytes specific for autologous Epstein-Barr virus in HIV-infected patients: the feasibility study of EBV-specific immunotherapy for patients with EBV-associated lymphoma.
    Hansasuta P; Incomserb P; Buranapraditkun S; Bhattarakosol P
    J Med Assoc Thai; 2004 Sep; 87 Suppl 2():S146-51. PubMed ID: 16083179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapeutic strategies for EBV-associated malignancies.
    Khanna R; Tellam J; Duraiswamy J; Cooper L
    Trends Mol Med; 2001 Jun; 7(6):270-6. PubMed ID: 11378517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.